

PRESSURE BIOSCIENCES INC.

14 Norfolk Avenue
South Easton, MA 02375
(T) 508-230-1828
(F) 508-230-1829
info@pressurebiosciences.com

Mr. Richard T. Schumacher, CEO, President
Dr. Edmund Y. Ting, SVP of Engineering
Dr. Alexander V. Lazarev, Chief Science Officer
Dr. Bradford A. Young, Chief Commercial Officer
Mr. Richard Thomley, Financial Advisor (ex-CFO)

STOCK OVERVIEW

Symbol:	PBIO	Recent Close:	\$3.77 (as of 03/12/19)
Exchange:	OTCQB	52-Week Range:	\$1.52 - \$4.94
Shares OS ¹ :	1.8M (8M FD)	Market Capitalization ² :	\$6.8M (\$30M FD)
Float:	~1.7M	Fiscal Year End:	December 31
Revenue (FY2017):	\$2.24M	Transfer Agent:	Computershare

COMPANY OVERVIEW

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. Our products/services are based on three patented, pressure-enhanced platforms: (i) Pressure Cycling Technology ("PCT"), (ii) Barofold Technology ("Barofold"), and (iii) Ultra Shear Technology ("UST").

The PCT Platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). Our primary focus is in making our recently-released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization and quality control of biotherapeutic drugs. The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in approximately 200 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders. The PCT Platform is offered through the Company's Research Products & Services Group.

The Barofold Platform can be used to significantly impact and improve the quality of protein therapeutics. It employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. The Barofold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. The Barofold Platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. It is scaleable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations. Research and manufacturing licenses are available.

The UST Platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.

1. Shares Outstanding (as of December 31, 2018) – includes approximately 1.8M common shares and 6.2M common share equivalents from Preferred Stock Series D, G, H, J, K, and AA on an as-converted basis.
2. Fully Diluted Market Capitalization is calculated using Common Stock OS and Common Equivalent Shares OS on a Fully Diluted basis.

INVESTMENT HIGHLIGHTS

- Seasoned Management Team & Board of Directors
 - Novel, Enabling, Patent Protected, Proprietary Pressure-based Platforms
 - Proven Core Technology with Multiple Applications (Over 300 PCT Systems Installed)
 - Razor/Razorblade Business Model
 - Sales into the Research Market (fast market penetration with minimal approvals required)
 - Increasing Number of 3rd Party Publications from Marquee Laboratories
 - PCT Breaks Through Bottlenecks to Enable and Accelerate Scientific Discovery & QC in Drug Development
 - Barofold Technology Can Impact and Improve Protein Drug Therapeutics
 - UST Offers the Potential to Produce Highly Stable Nanoemulsions in Many Markets, Including Food and CBD
 - Significant Market Opportunity (~\$6 Billion from ~500K Scientists in 80K Labs Worldwide)
-

RECENT & KEY ANNOUNCEMENTS (2019/2018)

- March 4: the Company announced a collaboration with the world renown Steinbeis Centre (Germany) to develop a revolutionary method based on optimizing disease-fighting antibodies. The method will combine PBI's patented PCT platform with the Centre's innovative PROTEX-MS platform.
 - February 21: the Company released scientific analyses confirming important benefits from processing CBD Oil with PBI's UST platform: analyses showed UST-prepared CBD Oil solutions met challenging nanoemulsion specifications and exhibited minimal loss during processing.
 - February 13: the Company announced the release of a short video demonstrating the use of its prototype UST platform to make water-soluble CBD Oil, offering a solution to CBD Absorption Issues in food and beverages.
 - January 29: the Company announced a collaboration with nutraceuticals manufacturer NutraFuels, Inc. for the development of high quality, water-soluble nanoemulsion-based nutraceuticals.
 - January 24: the Company announced that a record number of scientific papers citing the significant benefits of PBI's PCT technology platform were published in 2018, some by global Key Opinion Leaders (KOLs).
 - **January 7, 2019:** the Company announced commercial launch of its unique biopharmaceuticals contract services business, offering improved manufacturing for protein therapeutic candidates (a \$250B global market).
 - December 18: Major International Research Center Reported that the Company's PCT Platform Could Play a Significant Role in Improving Cancer Diagnosis and Treatment
 - November 20: Uptick Newswire announced interview with Richard T. Schumacher on Stock Day Podcast. The interview focused on PBI's proprietary Ultra Shear Technology (UST) platform and the two milestones achieved over the past several weeks: (i) development of first working prototype UST instrument, and (ii) development of proprietary UST method to make CBD Oil truly soluble in Water (a "nanoemulsion").
 - November 15: the Company achieved the successful development of a proprietary method for high quality, water soluble oils, which it believed could open up major new opportunities in multiple markets. The Company also said that the initial focus of the new method would be in the CBD Oil and cosmetics markets.
 - November 9: the Company announced achievement of the first major milestone in the development of its Ultra Shear Technology ("UST") Program: development of the first working prototype of the UST Platform System.
 - November 7: Bradford A. Young, Ph.D., MBA joined PBI as Chief Commercial Officer, where his strong technical and leadership experience is expected to help drive product adoption and accelerate revenue growth.
 - October 3: the Company announced an acceleration in the development timetable for its novel Ultra Shear Technology ("UST") platform, in order to pursue commercialization of the technology into major new markets.
 - September 13: the Company announced the commercial release of the HUB880 Explorer, its newest high pressure instrument that is expected to enhance high pressure processing studies for food safety and quality, as well as guide development of PBI's Ultra Shear Technology Platform.
 - August 30: the Company was awarded a key US patent for a novel, high-pressure flow-through microfluidic sample preparation device, which should open the path to the development of automated "hands-free" sample preparation workflows utilizing the Company's patented high-pressure platform technologies.
 - August 15: the Company reported Q2 2018 financial results, including the 10th consecutive quarterly increase in products and services revenue, record second quarter total revenue of \$638,800 (18% increase over Q2 2017), increases in instrument sales, consumables and gross margin compared to Q2 2017, and a 24% decrease in operating loss from the same period in 2017.
 - July 19: the Company announced it was developing a potential breakthrough processing method - based on their patented Ultra Shear Technology - for high quality, shelf-stable milk and other dairy products that would not require refrigeration or chemical additives.
 - July 12: The Ohio State University announced they had been awarded an \$891,000 grant from the USDA to develop - together with PBI - an innovative manufacturing technology to preserve food and beverages using wholesome, recognizable ingredients, no artificial preservatives and reduced use of heat.
 - **June 12, 2018:** the Company announced the conversion an additional \$7.24M of Debt into Equity, making a total of \$13.6M of debt that the Company had converted into equity from mid-May to mid-June 2018.
-

BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

3/12/2019